APP and Down syndrome: Increased doses of APP resulting from duplication of chromosome 21 in Down syndrome are associated with an increased incidence of early-onset AD, which is accompanied by plasma metabolic alterations in purine deamination, carboxylic acids, and tryptophan metabolism as a function of inflammatory stimuli (e.g., IFN signaling) (27).